Literature DB >> 9063255

Abnormal expression of the p53 tumor suppressor gene in the conjunctiva of patients with pterygium.

D T Tan1, A S Lim, H S Goh, D R Smith.   

Abstract

PURPOSE: To determine whether pterygium is a disorder of abnormal growth by examining the expression of the p53 gene in the conjunctiva of patients with pterygium.
METHODS: Immunostaining for abnormal expression of p53 was performed using mouse monoclonal antibody to human p53, pAb 240, on six eyes with primary pterygium and two eyes with recurrent pterygium.
RESULTS: In three of the eight eyes with pterygium, specimens were positive for abnormal expression in the epithelium of the pterygium and in the superior bulbar conjunctiva.
CONCLUSION: Abnormal p53 expression in the epithelium of primary and recurrent pterygium specimens suggests that pterygium is a growth disorder rather than a degeneration.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9063255     DOI: 10.1016/s0002-9394(14)70141-2

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  36 in total

1.  Apoptosis and apoptosis related gene expression in normal conjunctiva and pterygium.

Authors:  D T Tan; W Y Tang; Y P Liu; H S Goh; D R Smith
Journal:  Br J Ophthalmol       Date:  2000-02       Impact factor: 4.638

2.  Pterygium in Indonesia: prevalence, severity and risk factors.

Authors:  G Gazzard; S-M Saw; M Farook; D Koh; D Widjaja; S-E Chia; C-Y Hong; D T H Tan
Journal:  Br J Ophthalmol       Date:  2002-12       Impact factor: 4.638

3.  No association of p53 codon 72 and p21 codon 31 polymorphisms in Taiwan Chinese patients with pterygium.

Authors:  Y Y Tsai; Y Y Tsai; Y W Cheng; H Lee; S H Tseng; C H Tsai; F J Tsai
Journal:  Br J Ophthalmol       Date:  2004-07       Impact factor: 4.638

4.  Prevalence of pinguecula and pterygium in a general population in Spain.

Authors:  E Viso; F Gude; M T Rodríguez-Ares
Journal:  Eye (Lond)       Date:  2010-12-24       Impact factor: 3.775

5.  Temporary amniotic membrane patch for the treatment of primary pterygium: mechanisms of reducing the recurrence rate.

Authors:  Juan Ye; Koung Hoon Kook; Ke Yao
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-09-17       Impact factor: 3.117

6.  Ophthalmic pterygium: a stem cell disorder with premalignant features.

Authors:  Jeanie Chui; Minas T Coroneo; Lien T Tat; Roger Crouch; Denis Wakefield; Nick Di Girolamo
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

7.  Outdoor work and the risk of pterygia: a case-control study.

Authors:  J Khoo; S M Saw; K Banerjee; S E Chia; D Tan
Journal:  Int Ophthalmol       Date:  1998       Impact factor: 2.031

8.  Pterygium and genetic polymorphisms of the DNA repair enzymes XRCC1, XPA, and XPD.

Authors:  Chun-Chi Chiang; Yi-Yu Tsai; Da-Tian Bau; Ya-Wen Cheng; Sung-Huei Tseng; Rou-Fen Wang; Fuu-Jen Tsai
Journal:  Mol Vis       Date:  2010-04-20       Impact factor: 2.367

9.  E-cadherin promoter hypermethylation may contribute to protein inactivation in pterygia.

Authors:  Chi-Hsien Young; Yu-Te Chiu; Tung-Sheng Shih; Wan-Ru Lin; Chun-Chi Chiang; Ying-Erh Chou; Ya-Wen Cheng; Yi-Yu Tsai
Journal:  Mol Vis       Date:  2010-06-09       Impact factor: 2.367

10.  Calcium-binding S100 protein expression in pterygium.

Authors:  Andri K Riau; Tina T Wong; Roger W Beuerman; Louis Tong
Journal:  Mol Vis       Date:  2009-02-16       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.